These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 19106164)
21. Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis. Matsuno H; Yoshida K; Ochiai A; Okamoto M J Rheumatol; 2007 Dec; 34(12):2326-33. PubMed ID: 18050387 [TBL] [Abstract][Full Text] [Related]
22. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. van Vollenhoven RF; Klareskog L Scand J Rheumatol; 2007; 36(6):418-23. PubMed ID: 18092261 [TBL] [Abstract][Full Text] [Related]
23. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Pavelka K; Jarosová K; Suchý D; Senolt L; Chroust K; Dusek L; Vencovský J Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624 [TBL] [Abstract][Full Text] [Related]
25. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. Kalb RE; Gurske J J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781 [TBL] [Abstract][Full Text] [Related]
26. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Elkayam O; Burke M; Vardinon N; Zakut V; Yitzhak RB; Paran D; Levartovsky D; Litinsky I; Caspi D Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336 [TBL] [Abstract][Full Text] [Related]
27. Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab. Ornetti P; Solau E; Gaudin P; Sibilia J; Berthelot JM; Puechal X; Tavernier C; Maillefert JF; Ann Rheum Dis; 2005 Sep; 64(9):1379-80. PubMed ID: 16100349 [No Abstract] [Full Text] [Related]
28. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. Westhovens R; Houssiau F; Joly J; Everitt DE; Zhu Y; Sisco D; Van Hartingsveldt B; Mascelli MA; Graham MA; Durez P; Bouman-Thio E J Rheumatol; 2006 May; 33(5):847-53. PubMed ID: 16583466 [TBL] [Abstract][Full Text] [Related]
29. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden. Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P Ann Rheum Dis; 2010 Feb; 69(2):352-7. PubMed ID: 19282310 [TBL] [Abstract][Full Text] [Related]
30. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516 [TBL] [Abstract][Full Text] [Related]
31. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Wong M; Oakley SP; Young L; Jiang BY; Wierzbicki A; Panayi G; Chowienczyk P; Kirkham B Ann Rheum Dis; 2009 Aug; 68(8):1277-84. PubMed ID: 18930987 [TBL] [Abstract][Full Text] [Related]
32. Dose intensification with infliximab in patients with rheumatoid arthritis. Berger A; Edelsberg J; Li TT; Maclean JR; Oster G Ann Pharmacother; 2005 Dec; 39(12):2021-5. PubMed ID: 16288073 [TBL] [Abstract][Full Text] [Related]
33. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis. Ideguchi H; Ohno S; Ishigatsubo Y J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533 [TBL] [Abstract][Full Text] [Related]
34. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Stamp LK; O'Donnell JL; Chapman PT; Zhang M; Frampton C; James J; Barclay ML Arthritis Rheum; 2009 Aug; 60(8):2248-56. PubMed ID: 19644853 [TBL] [Abstract][Full Text] [Related]
35. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. Voulgari PV; Venetsanopoulou AI; Exarchou SA; Alamanos Y; Tsifetaki N; Drosos AA Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499 [TBL] [Abstract][Full Text] [Related]
36. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Smolen JS; Han C; van der Heijde D; Emery P; Bathon JM; Keystone E; Kalden JR; Schiff M; Bala M; Baker D; Han J; Maini RN; St Clair EW Arthritis Rheum; 2006 Mar; 54(3):716-22. PubMed ID: 16508932 [TBL] [Abstract][Full Text] [Related]
37. Rituximab therapy in rheumatoid arthritis in daily practice. Assous N; Gossec L; Dieudé P; Meyer O; Dougados M; Kahan A; Allanore Y J Rheumatol; 2008 Jan; 35(1):31-4. PubMed ID: 18176989 [TBL] [Abstract][Full Text] [Related]
38. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Rahman MU; Strusberg I; Geusens P; Berman A; Yocum D; Baker D; Wagner C; Han J; Westhovens R Ann Rheum Dis; 2007 Sep; 66(9):1233-8. PubMed ID: 17392352 [TBL] [Abstract][Full Text] [Related]
39. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308 [TBL] [Abstract][Full Text] [Related]
40. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Kinder AJ; Hassell AB; Brand J; Brownfield A; Grove M; Shadforth MF Rheumatology (Oxford); 2005 Jan; 44(1):61-6. PubMed ID: 15611303 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]